Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Hospira (NYSE: HSP) is trading at unusually high volume Wednesday with 3.1 million shares changing hands. It is currently at 2.4 times its average daily volume and trading down 78 cents (-2.2%) at $34.17 as of 11:30 a.m. ET.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Hospira has a market cap of $5.84 billion and is part of the health care sector and drugs industry. Shares are up 13.1% year to date as of the close of trading on Tuesday. Hospira, Inc. provides injectable drugs and infusion technologies to develop, manufacture, distribute, and markets products that help improve the safety of patient care worldwide. TheStreet Ratings rates Hospira as a hold. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and a generally disappointing performance in the stock itself. You can view the full Hospira Ratings Report. See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center. It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.